FR0010417345 - Common Stock
DBV TECHNOLOGIES SA
EPA:DBV (11/8/2024, 7:00:00 PM)
0.7
-0.02 (-2.78%)
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 104 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
DBV TECHNOLOGIES SA
Batiment IRO, 107 Av. de la Republique
Chatillon AUVERGNE-RHONE-ALPES
P: 33155427878
Employees: 106
Website: https://www.dbv-technologies.com/
Find more stocks on Euronext Paris - Matif
Find more stocks on the EuroNext
Find more stocks on the European
Find competitors from the same sector on the EuroNext
Find competitors from the same industry on the EuroNext
Find stocks with similar TA and Setup ratings on the EuroNext
Find stocks with similar Fundamental rating on the EuroNext
Find the competitors with the best technical ratings on the EuroNext
Find the competitors with the best technical and setup ratings on the EuroNext
Find the competitors with the best fundamentals on the EuroNext
Find the competitors with the best valuation on the EuroNext
Find the competitors with the best dividend on the EuroNext
Find the competitors with the best analyst ratings on the EuroNext